| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/13/2013 | EP2556824A1 Solid pharmaceutical composition for buccal administration of agomelatine |
| 02/13/2013 | EP2556160A2 Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
| 02/13/2013 | EP2556083A2 Non-hormonal steroid modulators of nf- kappa b for treatment of disease |
| 02/13/2013 | EP2556082A2 Substituted androst-4-ene diones |
| 02/13/2013 | EP2556081A2 A cytosine analogue, a method of preparation of a cytosine analogue, a dna methyltransferase 1 inhibitor, a method for dna methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal dna methylation |
| 02/13/2013 | EP2556080A1 Cosmetic composition |
| 02/13/2013 | EP2556079A2 Polyol modified aminoglycoside-lipid conjugates |
| 02/13/2013 | EP2556076A2 Novel sultam compounds |
| 02/13/2013 | EP2556074A1 Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it |
| 02/13/2013 | EP2556072A1 2-phenyl benzothiazole linked imidazole compounds as potential anticancer agents and process for the preparation thereof |
| 02/13/2013 | EP2556071A1 Kinase inhibitors and method of treating cancer with same |
| 02/13/2013 | EP2556070A1 Synthesis of chiral 2-(1h-indazol-6-yl)-spiro[cyclopropane-1,3'- indolin]-2'-ones |
| 02/13/2013 | EP2556069A1 Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators |
| 02/13/2013 | EP2556068A1 P38 map kinase inhibitors |
| 02/13/2013 | EP2556067A2 Pyrazolyl ureas as p38 map kinase inhibitors |
| 02/13/2013 | EP2556066A1 Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| 02/13/2013 | EP2556065A1 Pyrazole p38 map kinase inhibitors |
| 02/13/2013 | EP2556063A1 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid salts |
| 02/13/2013 | EP2556059A1 Improved process for preparing valsartan |
| 02/13/2013 | EP2556058A1 Radioprotector compounds and methods |
| 02/13/2013 | EP2556057A1 7,11-methanocycloocta [b]quinoline derivative as highly functionalizable acetylcholinesterase inhibitors |
| 02/13/2013 | EP2556056A1 Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| 02/13/2013 | EP2556055A2 Ship inhibitors and uses thereof |
| 02/13/2013 | EP2556054A1 Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3 |
| 02/13/2013 | EP2556053A2 (20s)-2-methylene-19-nor-22-dimethyl-1alpha,25- dihydroxyvitamin d3 and (20r)-2-methylene-19-nor-22-dimethyl-1alpha,25-hydroxyvitamin d3 |
| 02/13/2013 | EP2556043A2 New polyterpene type compounds, compositions containing them and topical uses thereof |
| 02/13/2013 | EP2555808A1 Fillers comprising gellan or pectin beads |
| 02/13/2013 | EP2555780A1 Gamma-polyglutamic acid-based ocular irrigating solutions |
| 02/13/2013 | EP2555779A1 Glycomimetic compounds and methods to inhibit infection by hiv |
| 02/13/2013 | EP2555778A1 Compositions and methods for inhibiting expression of cd274/pd-l1 gene |
| 02/13/2013 | EP2555777A1 Novel single chemical entities and methods for delivery of oligonucleotides |
| 02/13/2013 | EP2555776A1 Combination compositions of adenosine a1 agonists and non-selective beta-adrenergic receptor blockers for reducing intraocular pressure |
| 02/13/2013 | EP2555775A1 Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure |
| 02/13/2013 | EP2555774A1 Combinations of medicaments, containing pde4 inhibitors and ep4 receptor antagonists |
| 02/13/2013 | EP2555773A1 Combinations of medicaments, containing pde4 inhibitors and ep4 receptor antagonists |
| 02/13/2013 | EP2555772A1 Oxazole derivatives useful as modulators of faah |
| 02/13/2013 | EP2555771A1 Pharmaceutical compositions highly dosed with biotin |
| 02/13/2013 | EP2555770A1 Ketorolac compositions for corneal wound healing |
| 02/13/2013 | EP2555769A2 Methods for treating respiratory viral infection |
| 02/13/2013 | EP2555768A2 Ire-1 inhibitors |
| 02/13/2013 | EP2555767A2 Methods of treatment using 3-bromopyruvate and other selective inhibitors of atp production |
| 02/13/2013 | EP2555766A2 Antimetastatic compounds |
| 02/13/2013 | EP2555765A1 Treatment of ataxia telangiectasia |
| 02/13/2013 | EP2555764A1 Antimicrobial compounds of 1,4- naphtoquinone structure |
| 02/13/2013 | EP2555763A1 Viral inhibitor compositions for in vivo therapeutic use comprising a combination of (-) -carvone, geraniol and a further essential oil component |
| 02/13/2013 | EP2555760A1 Methods and compositions for treating wounds utilizing chitosan compounds |
| 02/13/2013 | EP2555757A2 Atazanavir sulfate formulations with improved ph effect |
| 02/13/2013 | EP2555756A2 Controlled release pharmaceutical compositions of tapentadol |
| 02/13/2013 | EP2555625A1 Process for preparing benzoxaboroles |
| 02/13/2013 | EP2555622A1 Hepatitis c virus inhibitors |
| 02/13/2013 | EP2555620A1 Sophorolipid analog compositions |
| 02/13/2013 | EP2555618A1 Methods of using diacerein as an adjunctive therapy for diabetes |
| 02/13/2013 | EP2555617A1 Novel hypoglycemic compounds |
| 02/13/2013 | EP2555616A1 Process for the preparation of memantine hydrochloride |
| 02/13/2013 | CN1893982B Menthol-containing preparation |
| 02/13/2013 | CN102933711A Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT) |
| 02/13/2013 | CN102933658A Local delivery of drugs from self assembled coatings |
| 02/13/2013 | CN102933593A Method of reducing intraocular pressure in humans using n6-cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof |
| 02/13/2013 | CN102933592A Crystalline form for diphenylmethane sglt2 inhibitor |
| 02/13/2013 | CN102933586A Nitroimidazole derivatives |
| 02/13/2013 | CN102933584A Pyrrolopyrazinone inhibitors of kinases |
| 02/13/2013 | CN102933583A Heteroaryl imidazolone derivatives as JAK inhibitors |
| 02/13/2013 | CN102933579A New ccr2 receptor antagonists and uses thereof |
| 02/13/2013 | CN102933576A Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators |
| 02/13/2013 | CN102933575A Yclohexyl-azetidinyl antagonists of ccr2 |
| 02/13/2013 | CN102933573A Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof |
| 02/13/2013 | CN102933572A Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
| 02/13/2013 | CN102933571A Phthalazin-(2h)-one inhibitors of kinases |
| 02/13/2013 | CN102933570A Method for producing (2r)-2-fluoro-2-c-methyl-d-ribono-y-lactone precursor |
| 02/13/2013 | CN102933564A 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace) |
| 02/13/2013 | CN102933561A Pharmaceutically active disubstituted triazine derivatives |
| 02/13/2013 | CN102933560A 4,6-dibenzamido-2-methyl-pyridine derivatives and applications to cancer treatment |
| 02/13/2013 | CN102933559A Optically active dibenzylamine derivative, and manufacturing method for same |
| 02/13/2013 | CN102933558A Reverse amide compounds as protein deacetylase inhibitor and methods of use thereof |
| 02/13/2013 | CN102933557A Radioprotector compounds and methods |
| 02/13/2013 | CN102933553A 7,11-methanocycloocta [b] quinoline derivative as highly functionalizable acetylcholinesterase inhibitors |
| 02/13/2013 | CN102933551A Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
| 02/13/2013 | CN102933548A Carboxamide compounds and their use as calpain inhibitors |
| 02/13/2013 | CN102933258A Radiotherapy combined with hypoxic cell sensitizers |
| 02/13/2013 | CN102933237A Conjugates for the prevention or treatment of nicotine addiction |
| 02/13/2013 | CN102933235A Halogenated ether complex |
| 02/13/2013 | CN102933233A Agent for treating renal fibrosis |
| 02/13/2013 | CN102933225A Surfactant composition |
| 02/13/2013 | CN102933220A Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure |
| 02/13/2013 | CN102933219A Manufacturing method for polyphenol composition |
| 02/13/2013 | CN102933218A Posology and administration of glucocorticoid based compositions |
| 02/13/2013 | CN102933217A Pharmaceutical composition for treating macular edema |
| 02/13/2013 | CN102933216A Anti-brain-tumor drug |
| 02/13/2013 | CN102933215A Treatment of type 2 diabetes |
| 02/13/2013 | CN102933214A 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (dpp-1) |
| 02/13/2013 | CN102933213A Radiation sensitiser compositions |
| 02/13/2013 | CN102933212A Novel combination and use |
| 02/13/2013 | CN102933211A Photo-inactivated viruses and systems and methods of using same |
| 02/13/2013 | CN102933210A Wake-time-extending agent |
| 02/13/2013 | CN102933205A Cilostazol cocrystals and compositions |
| 02/13/2013 | CN102933204A Coated particle and method for producing coated particle |
| 02/13/2013 | CN102933201A Antimycotic pharmaceutical composition |
| 02/13/2013 | CN102933199A Nicotine-containing pharmaceutical compositions |
| 02/13/2013 | CN102933198A Formulations comprising triptan compounds |
| 02/13/2013 | CN102933192A Topical pharmaceutical or cosmetic composition useful for the treatment of diseases or conditions that transcur through a deficit of maturation of the cornified envelope |